Literature DB >> 11173635

HLA-DR2 Frequency Increase in Severe Aplastic Anemia Patients is Mainly Attributed to the Prevalence of DR15 Subtype.

Sergey I Kapustin1, Tamara I Popova, Anton A Lyschov, Alexander V Togo, Kudrat M Abdulkadyrov, Michail N Blinov.   

Abstract

The association between severe aplastic anemia (AA) and DR2 antigen seems to be well established. However, since discrimination between two DR2-associated splits, namely DR15 and DR16, rarely was performed, it remains unclear whether one or both of these subvariants are responsible for AA susceptibility. In this study, we have analyzed the HLA-DR allelic distribution in a group of 37 AA patients of slavic origin from North-Western Russia. The experimental design included PCR-based amplification of DRB-specific sequences, followed by reverse dot-blot hybridization of the biotinylated PCR-product with the set of sequence-specific oligonucleotide probes. HLA-DRB alleles were identified by non-radioactive enzymatic reaction, then standard serological specificities of HLA-DR antigen were estimated according to the WHO nomenclature. Whereas DR15 subtype occurred more often in the patients (23.0% vs. 13.3%, p< 0.05), DR16 split did not show the same tendency. The results, show the overall predominance of HLA-DR2 specificity (DR15+DR16) did not reach statistical significance (24.4% vs.17.5%, p<0.2). Thus, we conclude that repeatedly reported DR2 frequency increase in AA patients is mainly attributed to the prevalence of DR15 subtype.

Entities:  

Year:  1997        PMID: 11173635     DOI: 10.1007/bf02907803

Source DB:  PubMed          Journal:  Pathol Oncol Res        ISSN: 1219-4956            Impact factor:   3.201


  23 in total

1.  Hla antigens and haplotypes in 200 patients with aplastic anemia.

Authors:  E Albert; E D Thomas; B Nisperos; R Storb; B M Camitta; R Parkman
Journal:  Transplantation       Date:  1976-11       Impact factor: 4.939

2.  A simple salting out procedure for extracting DNA from human nucleated cells.

Authors:  S A Miller; D D Dykes; H F Polesky
Journal:  Nucleic Acids Res       Date:  1988-02-11       Impact factor: 16.971

3.  Does HLA-DR predict response to specific immunosuppressive therapy in aplastic anaemia?

Authors:  F P Rugman; D Ashby; J M Davies
Journal:  Br J Haematol       Date:  1990-04       Impact factor: 6.998

4.  Aplastic anaemia in the Orient.

Authors:  N S Young; S Issaragrasil; C W Chieh; F Takaku
Journal:  Br J Haematol       Date:  1986-01       Impact factor: 6.998

Review 5.  The analysis of restriction fragment length polymorphism in human cancer: a review from an epidemiological perspective.

Authors:  P Vineis; N Caporaso
Journal:  Int J Cancer       Date:  1991-01-02       Impact factor: 7.396

6.  HLA-DR frequency in Turkish aplastic anemia patients and the impact of HLA-DR2 positivity in response rate in patients receiving immunosuppressive therapy.

Authors:  O Ilhan; M Beksaç; H Koç; H Akan; A Keskin; O Arslan; G Gürman; M Ozcan; N Konuk; A Uysal
Journal:  Blood       Date:  1995-09-01       Impact factor: 22.113

7.  HLA associations in Italian and non-Italian Caucasoid aplastic anaemia patients.

Authors:  J D'Amaro; J J van Rood; A A Rimm; M M Bortin
Journal:  Tissue Antigens       Date:  1983-03

8.  Aplastic anemia and non-A, non-B hepatitis.

Authors:  J B Zeldis; J L Dienstag; R P Gale
Journal:  Am J Med       Date:  1983-01       Impact factor: 4.965

9.  Response to immunosuppressive therapy and an HLA-DRB1 allele in patients with aplastic anaemia: HLA-DRB1*1501 does not predict response to antithymocyte globulin.

Authors:  S Nakao; A Takami; N Sugimori; M Ueda; S Shiobara; T Matsuda; H Mizoguchi
Journal:  Br J Haematol       Date:  1996-01       Impact factor: 6.998

10.  In vitro tests for distinguishing possible immune-mediated aplastic anemia from transfusion-induced sensitization.

Authors:  B J Torok-Storb; C Sieff; R Storb; J Adamson; E D Thomas
Journal:  Blood       Date:  1980-02       Impact factor: 22.113

View more
  3 in total

Review 1.  The diagnosis and treatment of aplastic anemia: a review.

Authors:  Maurizio Miano; Carlo Dufour
Journal:  Int J Hematol       Date:  2015-04-03       Impact factor: 2.490

2.  Immune dysregulation in myelodysplastic syndrome.

Authors:  Chiharu Sugimori; Alan F List; Pearlie K Epling-Burnette
Journal:  Hematol Rep       Date:  2010-01-26

3.  Acquired aplastic anemia complicated with anti-glomerular basement membrane disease successfully treated with immunosuppressive therapy: a case report.

Authors:  Kenji Matsui; Wataru Kamata; Yasuhiro Mochida; Kunihiro Ishioka; Hidekazu Moriya; Sumi Hidaka; Takayasu Ohtake; Yotaro Tamai; Shuzo Kobayashi
Journal:  BMC Nephrol       Date:  2022-04-07       Impact factor: 2.388

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.